

## numares completes another financing round

**Regensburg, 26 July 2016. numares AG, a system provider of innovative in-vitro diagnostic systems based in Regensburg, Germany, has successfully completed another financing round. The investors include Wachstumsfonds Bayern, a Bavarian growth fund managed by Bayern Kapital that will provide €2 million. The additional funds will be used to expand the development pipeline and fuel the company's continued international expansion.**

numares AG, a company that is based in Regensburg, Germany, and operates branches in the United States, develops and markets integrated test systems for human diagnostics based on nuclear magnetic resonance spectroscopy (NMR). The diagnostic tests interpret patients' individual metabolism profiles using numares' proprietary MGS technology. The results of these tests provide valuable insights into the origin, extent and seriousness of diseases. As evidence to the cost efficiency of numares' NMR-based test systems, a broad range of different tests can be conducted on the very same system – a fully automatic process with high throughput. The company employs about 50 people. In the past two years, more than 900,000 tests were billed and 16 AXINON<sup>®</sup> test systems were sold.

Ilse Aigner, Bavaria's Minister of Economic Affairs, said: "We are really glad that with numares we support an innovative high-tech company from Bavaria. The company is in the best-possible position to succeed in the global diagnostics market with its promising technology. Bayern Kapital, the venture capital organization of the state of Bavaria, has stood by numares from the very start. With the Wachstumsfonds Bayern, we are now helping numares to carry out its international expansion plans - as a result cutting-edge technology made in Bavaria can be used around the world."

Dr. Georg Ried, Managing Director of Bayern Kapital, added: "The Regensburg-based diagnostic experts at numares have developed a highly innovative technology that has tremendous growth potential. It enables physicians, hospitals and laboratories to gain a broad range of information about the diseases and risk factors of their patients. Tapping new markets represents a consistent step in the further growth of numares. We are happy to assist the company by providing funds from the Wachstumsfonds Bayern."

Dr. Volker Pfahlert, Executive President of numares AG, also expressed his satisfaction with the decision. "We are really happy about the successful conclusion to this round of financing," Pfahlert said. "These funds represent a tremendous vote of confidence in numares' technology. After successfully introducing our technology to the U.S. market, we are now working intensely on the commercialization of numares' test systems in Europe and Asia. This effort has already produced some initial and important successes. We are also focusing our work on expanding our test pipeline to increase the therapeutic spectrum." The tightly regulated market in Europe and the specific conditions of the Asian market represent the next challenges that the company must face in its efforts to establish its diagnostics technology in laboratory medicine.

**About numares:**

**numares** is a specialized developer and provider of analytic and diagnostic test systems based on nuclear magnetic resonance (NMR) spectroscopy and numares' proprietary Magnetic Group Signaling (MGS) technology.

**numares HEALTH** develops and markets in-vitro diagnostic tests with the CE-marking and integrated test systems for high-throughput use in clinical diagnostics and life science research. The highly standardized tests provide valuable information on the disease status of patients in the indication areas of cardiovascular disease, nephrology and oncology.

In addition, **numares HEALTH** provides its test systems to the pharmaceutical industry on a fee-for-service basis. They can be used for example to investigate the therapeutic effects of medication as part of clinical trials. Furthermore, the company supports customers with complex issues and clinical trials, drawing on its many years of expertise and experience in the area of NMR spectroscopy and metabolomics.

[www.numares.com](http://www.numares.com)

**Media contact:**

numares AG  
Dipl.-Biol. Christiane Proll, MBA  
Tel.: +49 941 2809 49-14  
E-mail: [christiane.proll@numares.com](mailto:christiane.proll@numares.com)

IRA WÜLFING KOMMUNIKATION GmbH  
Dr. Reinhard Saller  
Tel.: +49 89 2000 30-30  
E-mail: [reinhard.saller@wuelfing-kommunikation.de](mailto:reinhard.saller@wuelfing-kommunikation.de)